The Day In Review: Biotech Ekes Out A Gain

December 30, 2004 In the last trading session of the year, Biotech was little changed from where it began. If it had been a Phase III trial, today’s index action would have been termed not statistically significant. At the close, the Centient Biotech 200 was 1.18 points higher at 3612.41, a gain of .03%. We look at the big gain for CoTherix, now the second best IPO of 2004, the story behind Immtech, which also had a big rise, StemCells and Aastrom, the biomarkers of the stem cell industry, and Biomira, which closed out the year with a 10% rise.

Back to news